Gene Therapy Shows Promise for Hereditary Spastic Paraplegia in Preclinical Study
核心洞察
Researchers from Drexel University and UMass Chan Medical School achieved proof-of-principle success with "silence and replace" gene therapy for SPG4 (搜索), the most common form of hereditary spastic paraplegia (搜索).
The viral vector-based approach prevented nerve breakdown and symptoms in a mouse model by silencing mutated SPAST (搜索) genes and replacing them with healthy versions.
The therapy successfully prevented gait defects and degenerative symptoms when administered to newborn mice before symptom onset.
Researchers from Drexel University's College of Medicine and UMass Chan Medical School have demonstrated proof-of-principle success with a novel "silence and replace" gene therapy approach for hereditary spastic paraplegia (搜索) (HSP (搜索)), a rare neurological disorder affecting an estimated 1 to 5 individuals per 100,000 worldwide. The findings, published in Molecular Therapy, represent a significant advance for a condition that currently has no cure.
The collaborative team, led by Drexel College of Medicine Professor Peter Baas, PhD, and Research Instructor Emanuela Piermarini, PhD, focused on SPG4 (搜索), the most common form of HSP (搜索) that accounts for approximately 40% of cases and is caused by mutations in the SPAST (搜索) gene. Using a viral vector delivery system, the researchers successfully prevented nerve breakdown and HSP symptoms in a mouse model of the disease.
Novel Therapeutic Approach
The "silence and replace" strategy employs a viral vector containing both micro-RNA components that silence the expression of mutated SPAST (搜索) genes and complementary DNA (cDNA) that replaces them with normal human SPAST gene expression. The SPAST gene encodes spastin (搜索), a microtubule-severing protein essential for healthy nerve cell function.
"The protein encoded by the SPAST (搜索) gene is a microtubule-severing protein that is vital for healthy function of nerve cells," explained Baas. "When SPAST mutations occur, and more than 200 different mutations have been identified, certain nerve cells are unable to maintain long axons — which comprise the long tracts that act as connections between the brain, spinal cord and legs — leading to this disease."
The research team previously developed a mouse model by introducing the human mutant SPAST (搜索) gene into mice, which subsequently developed gait defects similar to those experienced by human patients. In the current study, researchers introduced the therapeutic vector into newborn mice before symptom onset, demonstrating that the technology could effectively shut down the faulty gene and replace it with healthy gene expression.
Promising Preclinical Results
The treated mice grew up without developing any gait defects or degenerative symptoms typically associated with HSP (搜索). This proof-of-principle success validates the therapeutic approach's potential to prevent disease progression when administered before symptom onset.
HSP (搜索) presents with varying severity and typically worsens over time. Patients are generally categorized as having uncomplicated HSP, characterized by gait defects such as muscle stiffness and weakness in leg muscles, or complicated HSP, which additionally may include symptoms affecting upper limb mobility, speech, intellectual abilities, and bladder control. Disease onset varies significantly, with some patients first experiencing symptoms in their senior years while others develop symptoms during childhood.
Translation Challenges
Despite the encouraging preclinical results, translating this discovery to human patients presents significant challenges. "As spastin (搜索) is a microtubule-severing protein, too much expression would destroy the microtubules and kills the cells," noted Baas. "The variant of spastin that becomes disease-causing when mutated also becomes long-lived and can accumulate in the nerve tracts."
The complexity extends beyond gene expression control. Turning off expression from the mutant gene may not necessarily lead to degradation of existing mutant protein, and spinal tracts that have already degenerated may not regenerate solely through successful gene silencing and replacement.
Comprehensive Treatment Strategy
To address these challenges, the research team is developing a multi-pronged approach. Piermarini is working on blood biomarkers to monitor disease progression and determine optimal timing for therapy initiation and efficacy assessment. The team is also developing complementary therapies aimed at degrading mutant protein that has already accumulated in nerve tracts.
Future plans include testing the gene therapy in symptomatic mice, which presents greater challenges due to existing axonal damage. The researchers anticipate that combination approaches incorporating exercise therapy, neurotrophins, and neurostimulation may be necessary to restore lost neurological function in areas such as speech and movement.
Research Collaboration and Support
The collaboration between Drexel University and UMass Chan Medical School was facilitated by patient advocacy groups, highlighting the crucial role of families and foundations in driving research forward. "Our two teams were introduced by parents of children with SPG4 (搜索) who created foundations seeking therapies or cures for their children," said Baas.
The research team included co-senior author Miguel Sena-Esteves, PhD, from UMass Chan Medical School, along with additional contributors Shrobona Guha, PhD, and Liang Qiang, MD, PhD, from Drexel's College of Medicine, and Heather Gray-Edwards, DVM, PhD, from UMass Chan Medical School.
The work received support from multiple organizations including the Spastic Paraplegia Foundation (搜索), the NIH National Institute of Neurological Disorders and Stroke (搜索), the Cure SPG4 Foundation (搜索), the Lilly and Blair Foundation, SPG4 (搜索) Cure for Jack Laidlaw, and the Maurya Koduri Foundation.
"The success we're seeing with gene therapy is exciting but will take more work to optimize for human patients," concluded Baas. "It's important that we continue developing this and other therapies, so we get help for patients as soon as possible."